For Glenmark, US sales growth pickup holds key to driving earnings prospects1 min read 15 Feb 2022, 01:19 PM IST
Glenmark’s domestic formulation sales grew by about 14% year on year, while US sales declined 3%. It did well in rest of the world and European markets with sales growing 21-24%.
Glenmark Pharmaceuticals Ltd's stock has corrected more than 30% from its 52-week high in July 2021. With the extraordinary gain momentum, seen during the first half of the year amid sales of covid treatment drugs, declining, investors await fresh triggers on earnings growth.
Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!Let’s get started